Improvement of cardio-ankle vascular index by glimepiride in type 2 diabetic patients

International Journal of Clinical Practice

Volumn 64, Issue 13, 2010, Pages 1796-1801

  Nagayama, D ^a   Saiki, A ^a   Endo, K ^a   Yamaguchi, T ^a   Ban, N ^a   Kawana, H ^a   Ohira, M ^a   Oyama, T ^a   Miyashita, Y ^a   Shirai, K ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; GLIBENCLAMIDE; GLIMEPIRIDE; LIPOPROTEIN LIPASE; SULFONYLUREA;

ADULT; ARTERIAL STIFFNESS; ARTICLE; CARDIOANKLE VASCULAR INDEX; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; URINALYSIS;

AGED; ANKLE; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; VASCULAR RESISTANCE; VASCULAR STIFFNESS;

EID: 78649266945     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02399.x     Document Type: Article

References (33)

1. Laakso M, Lehto S,. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atheroclerosis 1998; 137: 65 - 73.
2. Woodfield S, Lundergan C, Reiner J, et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J Am Coll Cardiol 1996; 28: 1661 - 9.
3. Saiki A, Oyama T, Endo K, et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 2007; 76: 93 - 101.
4. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752 - 61.
5. Fortuno A, Bidegain J, Jose GS, et al. Insulin resistance determines phagocytic adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. J Hypertens 2009; 27: 1420 - 30.
6. Rosskamp R, Wernicke-Pnten K, Draeger E,. Clinical profile of the novel sulfonylurea glimepiride. Diabetes Res Clin Pract 1996; 31: 33 - 42.
7. Draeger E, Wernicke-Panten K, Lomp HJ, Schuler E, Rosskamp R,. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride. Horm Metab Res 1996; 28: 419 - 25.
8. Scholzm GH, Schneider K, Knirsch W, Becker G,. Efficacy and tolerability of glimepiride in daily practice. Clin Drug Investig 2001; 21: 597 - 604.
9. Rosenstock J, Schneider J, Salmos E, Muscmore DB,. Glimepiride, a new once-daily practice. Diabetes Care 1996; 19: 1194 - 9.
10. Shakuto S, Sato Y, Ohshima K, Yaguchi M,. Atheroprotective effects of a new sulfonylurea of the third generation, glimepiride. J Diabet Complications 2001; 15: 68.
11. Shirai K, Utino J, Otsuka K, Tanaka M,. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J. Atheroscler. Thromb. 2006; 13: 1010 - 7.
12. Yambe T, Meng X, Hou X, et al. Cardio-ankle vascular index (CAVI) for the monitoring of the atherosclerosis after heart transplantation. Biomed Pharmacother 2005; 59: 177 - 9.
13. Kubozono T, Miyata M, Ueyama K, et al. Clinical significance and reproducibility of new arterial distensibility index. Circ J 2007; 71: 89 - 94.
14. Nakamura K, Tomaru T, Yamamura S, Miyashita Y, Shirai K, Noike H,. Cardio-ankle vascular index is a candidate predictor of coronary atherosclerosis. Circ J 2008; 27: 598 - 604.
15. Shirai K, Nema T, Hiroh Y, Itoh Y, Miyashita Y, Watanabe H,. Clinical efficacy of the direct assay method using polymers for serum high density lipoprotein cholesterols. J Clin Lab Anal 1992; 11: 82 - 6.
16. Kobayashi J, Hashimoto H, Fukamachi I, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chem Acta 1993; 216: 113 - 23.
17. Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 1997; 76: 365 - 74.
18. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439 - 46.
19. Horimoto H, Nakai Y, Mieno S, Nomura Y, Nakahara K, Sasaki S,. Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning. J Surg Res 2002; 15: 181 - 8.
20. Ibata J, Sasaki H, Kakimoto T, et al. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. Diabetes Res Clin Pract 2008; 870: 265 - 70.
21. Huang CL, Chen MF, Jeng JS, et al. Postchallenge hyperglycemic spike associate with arterial stiffness. Int J Clin Pract 2007; 61: 397 - 402.
22. Wu LL, Chiou CC, Chang PY, Wu JT,. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1 - 9.
23. Hayaishi Okano R, Yamasaki Y, Kajimoto Y, et al. Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. Diabetes Care 2003; 26: 458 - 63.
24. Nishikawa T, Sasahara T, Kiritoshi S, et al. Evaluation of urinary 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003; 26: 1507 - 12.
25. Negishi H, Ikeda K, Kuga S, et al. The relation of oxidative DNA damage to hypertension and other cardiovascular risk factors in Tanzania. J Hypertens 2001; 19: 529 - 33.
26. Endo K, Miyashita Y, Sasaki H, et al. Probucol and atorvastatin decrease urinary 8-Hydroxy-2′-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb 2005; 13: 68 - 75.
27. Oyama T, Miyashita Y, Watanabe H, Shirai K,. The role of polyol pathway in high glucose-induced endotherial cell damages. Diabetes Res Clin Pract 2006; 73: 227 - 34.
28. Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y,. Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-κB activation through a phosphoinoside 3-kinase-Akt-depent pathway. Diabetes Obes Metab 2009; 11: 143 - 9.
29. Delbosc S, Paizanis E, Magous R, et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis 2005; 179: 43 - 9.
30. Mohazzab KM, Kaminski PM, Wolin MS,. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994; 266: 2568 - 72.
31. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002; 105: 1656 - 62.
32. Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K,. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 1999; 145: 45 - 50.
33. Shirai K, Itoh Y, Sasaki H, et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 1999; 46: 35 - 41. (Pubitemid 29475000)